

**Table S2.** Clinical outcome

Study patient	Study cohort	Number of injections (a)	Type of injected lesion (b)	Response in injected lesion(s)	Overall response
myDCTV-01	C1	6	SC	PD	PD
myDCTV-02	C1	3	SC	SD	PD
myDCTV-03	C2	7	SC, LN	PD	PD
myDCTV-04	C2	8	ST	SD	PD
myDCTV-05	C3	7	SC	CR	CR
myDCTV-06	C3	4	SC	PR	PD
myDCTV-07	C3	6	SC	CR	CR
myDCTV-08	C4	5	LN	PD	PD (MR)
myDCTV-09	C4	6	SC	PD	PD
myDCTV-10	C4	11	SC	PR	PR
myDCTV-11	C4	8	LN	PR	PD
myDCTV-12	C4	10	C, LN	CR	PD (MR)
myDCTV-13	C4	6	LN	PD	PD

a Number of injections with talimogene laherparepvec; b Type of injected lesions that were measurable on PET/CT-imaging

according to iRECIST criteria. Abbreviations: C cutaneous; SC subcutaneous; LN lymph nodes; ST soft tissue; PD progressive disease;

SD stable disease; CR complete response; PR partial response; MR mixed response